Cytokine expression for T-cell promotion
Oncology
Pre-clinicalActive
Key Facts
About ExploRNA Therapeutics
ExploRNA Therapeutics is a private, pre-clinical stage biotech firm focused on pioneering innovations within the mRNA therapeutic platform. Its core business model combines a platform technology offering, through the sale of next-generation capping reagents (cap analogs), with internal therapeutic program development in oncology. Led by a team of renowned scientists from the University of Warsaw, including inventor Professor Jacek Jemielity, the company is strategically positioned to capitalize on the growing mRNA therapeutics market by both enabling partners and developing its own novel therapies.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |